Introduction
Current guidelines for the treatment of early-stage breast cancer recommend adjuvant chemotherapy for most patients with estrogen receptor (ER)-negative or HER2-positive tumors (1) (2) . In contrast, selecting chemotherapy for patients with ER-positive, HER2-negative disease is more challenging as these patients represent a wide spectrum of different risk profiles: Women who derive little benefit from chemotherapy in addition to endocrine therapy and women with high-risk disease where chemotherapy is very appropriate. Current guidelines recommend the use of validated multigene tests for the decision whether to add chemotherapy or not after consideration of conventional markers (1) .
Recently, several molecular tests for prediction of breast cancer prognosis have been developed in order to aid clinical decision making (3) (4) (5) . Some tests have been developed in heterogeneous patient cohorts (6) (7) . Therefore, a clear answer about their prognostic or predictive value in ER-positive and HER2-negative patients remains elusive, because all published validation results are based on cohorts that include HER2-positive patients.
Moreover, none of the tests published to date have been shown to outperform a combination of hormone receptors, HER2 and Ki67 assayed by immunohistochemistry.
Here, we present the validation of Endopredict (EP), a new RNA-based multigene score predicting the likelihood of distant recurrence in patients with early stage, ER-positive and HER2-negative breast cancer treated with adjuvant endocrine therapy only. The EP risk score and its combination with the clinical risk factors tumor size and nodal status (EPclin) were generated in a large training set of 964 tumor samples. The pre-specified risk scores
Methods

EP and EPclin risk scores
A detailed description of the training process of EP and Epclin risk scores including sample cohorts, selection of the final set of genes, algorithm generation, and threshold definition is shown in the supplementary appendix.
In brief, the final training set for the development of the EP and Epclin risk score consisted of 964 ER-positive, HER2-negative tumors from patients treated with adjuvant tamoxifen only.
Because the immunohistochemistry-based hormone receptor status was not available for all samples, selection was based on the ESR1/ERBB2 gene expression using pre-specified cutoff levels (supplementary appendix, section 2.4). In a top-down approach, we developed and defined the EP score consisting of 8 cancer-related genes of interest (GOI: BIRC5, UBE2C, DHCR7, RBBP8, IL6ST, AZGP1, MGP, STC2) and 3 normalization genes (CALM2, OAZ1, RPL37A) (Supplementary Tables S1, S4 ).
The design and calculation of the final pre-specified EP score as used for validation is described as follows: Mathematically, EP is arranged as a linear combination to predict distant recurrence (Supplementary Figure S4) . Relative expression of each GOI was assessed as delta cycle threshold (ΔCt) values based on normalization on the average of three reference genes (CALM2, OAZ1 and RPL37A):
The ΔCt values were combined into the predictive unscaled risk score s u .
To avoid negative score values, we defined the final, rescaled EP risk score (s). where t codes the tumor size (1: ≤1 cm, 2: >1 cm to ≤2 cm, 3: >2 cm to ≤5 cm, 4: >5 cm),
and n the nodal status (1: negative, 2: 1 to 3 positive nodes, 3: 4 to 10 positive nodes, 4: >10 positive nodes).
Thresholds for EP and EPclin to discriminate patients into low risk and high risk of distant recurrence were developed in the training set at 5 and 3.3, respectively, and pre-specified accordingly for validation.
Patients and tumor samples of the validation cohorts
The present investigation is part of the ABCSG translational research program (abcsg.research). Women included in the validation sets had participated in ABCSG-6
(tamoxifen-only arm) or ABCSG-8 trial and received either tamoxifen for 5 years or tamoxifen for 2 years followed by anastrozole for 3 years. Inclusion criteria and the main clinical results of these trials were reported previously (8) (9) ABCSG-6 was a randomized phase III trial comparing tamoxifen alone for 5 years with tamoxifen in combination with aminoglutethimide for the first 2 years of treatment in postmenopausal women. In ABCSG-8, postmenopausal breast cancer patients were randomly assigned to receive either tamoxifen for 5 years or tamoxifen for 2 years followed by anastrozole for 3 years.
All FFPE tumor blocks were collected at the time of surgery prior to adjuvant therapy and were stored at room temperature. Approval was obtained from institutional review boards.
Tumor sections of 4-10 µm were cut. One section was stained by hematoxilin/eosin to confirm the presence of invasive carcinoma, and further sections were used for molecular analyses. Pathologists from participating ABCSG centers sent a representative FFPE tumor block from each woman to the central lab of abcsg.research at the Medical University of Vienna. Overall, twenty-four centers contributed samples (see Acknowledgements).
HER2 and Ki67 were assayed by immunohistochemistry and evaluated centrally in the abcsg.research lab at the Medical University of Vienna according to standard criteria (10-11).
For Ki67 samples a cutoff value 11% was used for dichotomization into low or high expression (12) . In case of HER2 2+ scores, FISH analyses were used to determine ERBB2 gene amplification.
RNA extraction and gene expression analysis with quantitative RT-PCR
Total RNA was extracted from one 5 or 10 µm whole FFPE tissue section with a silica beadbased, fully automated isolation method (Tissue Preparation System; VERSANT Tissue Preparation Reagents; Siemens Healthcare Diagnostics, Tarrytown, US) as described in supplementary appendix (13) . All samples were analyzed with quantitative one-step reverse transcription PCR (RT-qPCR) on an ABI PRISM® 7900HT (Applied Biosystems, Darmstadt, Germany) using SuperScript® III Platinum® One-Step Quantitative RT-PCR System with ROX (Invitrogen, Karlsruhe, Germany). All PCR assays were performed in triplicate (details see supplementary appendix). Normalized expression of GOI, EP and EPclin were calculated as described above (equations 1-4). 
Validation and statistical analyses
The two validation studies were performed using pre-specified objectives, assay methods, P-values to assess whether the EP score contains additional information on distant recurrence with respect to a fixed set of variables X are one-sided and based on the permutation test using 10,000 random permutations with null hypothesis "EP is not related to outcome" and the c-index as test statistic.
Statistical analyses were performed using SPSS software, version 15.0 (SPSS Inc., Chicago, USA) and MATLAB software, version R2009b (The MathWorks, Inc., Natick, USA).
Results
Validation of EP and EPclin in the ABCSG-6 and ABCSG-8 cohorts
The EP score was developed using gene expression data of 964 ER-positive, HER2-negative tumors (supplementary Figure S4 ; supplementary appendix, section 2) Using the pre-specified threshhold for discriminating samples into low or high risk of distant metastasis, the EP risk score was independently validated in two large randomized phase III trials. The relation between the EP risk score and distant recurrence was assessed by Cox models adjusted for age, tumor size, lymph node status, tumor grade, ER-, PR-, Ki67-expression (IHC), and type of adjuvant endocrine therapy. In these multivariate analyses, the EP risk score was an independent predictor of distant recurrence in ABCSG-6 and ABCSG-8 (Table 1) .
Subsequently, patients were dichotomized into EP-low and EP-high risk groups according to the cutoff value pre-specified in the training set.
In Kaplan-Meier analyses, we observed significant differences in distant recurrence between EP-low-risk and EP-high-risk patients in both trials (Figure 2A, 2C) . At 10 years, the distant recurrence rates for patients with EP-low and EP-high were 8% (3%-13%) and 22% (15%- 29%) in ABCSG-6 (P<0.001) and 6% (2%-9%) and 15% (11%-20%) in ABCSG-8 (P<0.001), respectively.
Additionally, the pre-specified Epclin score (combination of EP and the two clinical risk factors nodal status and tumor size) was also validated in the ABCSG-6 and ABCSG-8 co-horts.
Epclin is a continuous predictor of distant reurrence at 5 or 10 years ( Figure 1B ). Distant recurrence rates of patients with EPclin-low and EPclin-high were 4% (1%-8%) and 28% (20%-36%) in ABCSG-6 (P<0.001) and 4% (2%-5%) and 22% (15%-29%) in ABCSG-8 (P<0.001), respectively ( Figure 2B, 2D) .
Performance of EP in subgroups
In subgroup analyses, we assessed potential heterogeneities of the prognostic performance of the continuous EP risk score by Cox regression analyses adjusted for the clinical risk as calculated by Adjuvant!Online. As shown in Figure 3 , a higher EP risk score was associated with a significantly increased risk of distant recurrence in all analyzed subgroups including tumor size, nodal status, grading, Ki67 and ER expression. In addition, there was no heterogeneity among the tamoxifen-only arm of ABCSG-6 and both treatment arms of ABCSG-8.
Exploratory subgroup analyses were performed using Kaplan-Meier analyses with dichotomized EP-low and EP-high risk groups. We found significant differences in distant recurrence between EP-low-risk and EP-high-risk patients in small (T1) and large (T2/T3) tumors, in node-negative and node positive patients, in grade 1 and 2, in ER low (<80%) and high (>80%), in Ki67 low (<11%, luminal A) tumors as well as in Adjuvant!Online low (<9%) and high (>9%) patients (Supplementary Figure S9) . The continuous relation between the respective score and the probability of developing a distant recurrence within the first 5 and 10 years after surgery is described by an independent model for each score generated from all ABCSG-6 and ABCSG-8 data (n=1702). The model is based on fitting the logarithm of the baseline cumulative hazard function by a cubic spline being a function of the logarithm of (event) time as proposed elsewhere (17) . For both scores independently, the model describing the data best was found as having two degrees of freedom for the splines, the score as linear covariate, and no interaction between time and score. confidence interval for the unit hazard ratio of the respective variable while column "P-value" contains the P-value for the probability of the regression coefficient to be zero.
Variables/units were coded according to table S6 in the supplementary appendix.
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